Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT105 in Refractory Lupus Nephritis
NCT07517536Enrolling by invitation
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CHT105 in lupus nephritis (LN), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Safety of CHT105 Injection at 52 weeks. Started Apr 2026; status: enrolling by invitation.
02
Drugs
CHT105
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07517536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517536.